Which has the lower trailing P/E, CORT or EXEL?

EXEL has the lower trailing P/E: CORT trades at 290.55 and EXEL at 18.45. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CORT or EXEL?

Over the past five years, CORT grew revenue faster — CORT at a 19.35% CAGR versus EXEL at 16.06%.

Is CORT or EXEL more profitable?

EXEL runs the higher net margin — CORT at 6.61% versus EXEL at 35.33%.

How have CORT and EXEL total returns compared?

Over the past 10 years, CORT delivered 33.70% and EXEL delivered 16.20% annualized total return. Past performance doesn't predict future results.

Corcept Therapeutics Incorporated (CORT) vs Exelixis, Inc. (EXEL)

A side-by-side comparison of Corcept Therapeutics Incorporated and Exelixis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CORT

Corcept Therapeutics Incorporated

$13.19B

$122.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

EXEL

Exelixis, Inc.

$14.79B

$58.85HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CORT vs EXEL

growth of $100 · dividends reinvested · last 10y

CORT +1837.0% (+34.5%/yr)EXEL +346.5% (+16.1%/yr)CORT compounded faster over this window

CORT EXEL

CORT vs EXEL: by the numbers

•EXEL is the larger company ($14.79B vs $13.19B market cap).
•EXEL trades at the lower trailing earnings multiple (18.45 vs 290.55 P/E), one valuation lens rather than an overall verdict.
•EXEL converts more revenue to profit (35.33% vs 6.61% net margin).
•CORT grew revenue faster over the past five years (19.35% vs 16.06% CAGR).

Metrics side by side

Valuation

Metric	CORT	EXEL
P/E ratio	290.55	18.45
Forward P/E	N/A	16.75
PEG ratio	N/A	0.36
P/S ratio	15.88	6.07
P/B ratio	18.69	8.02
EV / EBITDA	1483.24	14.68
FCF yield	0.81%	7.83%

Profitability

Metric	CORT	EXEL
Gross margin	98.30%	96.48%
Operating margin	0.77%	39.88%
Net margin	6.61%	35.33%
ROE	7.78%	46.68%
ROIC	0.87%	37.87%

Growth (annualized)

Metric	CORT	EXEL
Revenue CAGR (5Y)	19.35%	16.06%
EPS CAGR (5Y)	0.64%	51.51%
FCF CAGR (5Y)	-4.40%	39.63%
Total return CAGR (5Y)	43.90%	23.00%

Frequently asked

Which has the lower trailing P/E, CORT or EXEL?: EXEL has the lower trailing P/E: CORT trades at 290.55 and EXEL at 18.45. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CORT or EXEL?: Over the past five years, CORT grew revenue faster — CORT at a 19.35% CAGR versus EXEL at 16.06%.
Is CORT or EXEL more profitable?: EXEL runs the higher net margin — CORT at 6.61% versus EXEL at 35.33%.
How have CORT and EXEL total returns compared?: Over the past 10 years, CORT delivered 33.70% and EXEL delivered 16.20% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CORT analysis Full EXEL analysis Interactive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratio Exelixis P/E ratio Corcept Therapeutics ROE Exelixis ROE Corcept Therapeutics operating margin Exelixis operating margin Corcept Therapeutics revenue growth Exelixis revenue growth Corcept Therapeutics free cash flow Exelixis free cash flow

Corcept Therapeutics & Exelixis appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.